Neuroreceptor Imaging Studies in Schizophrenia

REFERENCES

• Davis K L, Kahn R S, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991; 148: 1474–86
   PubMed Web of Science ®Google Scholar
• Weinberger D R. Implications of the normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987; 44: 660–9
   PubMed Web of Science ®Google Scholar
• Mintun M A, Raichle M E, Kilbourn M R, Wooten G F, Welch M J. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 1984; 15: 217–27
   PubMed Web of Science ®Google Scholar
• Slifstein M, Laruelle M. Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. Nucl Med Biol 2001; 28: 595–608
   PubMed Web of Science ®Google Scholar
• Weinberger D R, Laruelle M. Neurochemical and neuropharmacological imaging in schizophrenia. Neuropharmacology—the fifth generation of progress, K L Davis, D S Charney, J T Coyle, C Nemeroff. Lippincott, Williams, & Wilkins, Philadelphia 2001
   Google Scholar
• Wong D F, Wagner H N, Tune L E, et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986; 234: 1558–63
   PubMed Web of Science ®Google Scholar
• Crawley J C, Owens D G, Crow T J, et al. Dopamine D2 receptors in schizophrenia studied in vivo. Lancet 1986; 2: 224–5
   PubMed Web of Science ®Google Scholar
• Blin J, Baron J C, Cambon H, et al. Striatal dopamine D2 receptors in tardive dyskinesia: PET study. J Neurol Neurosurg Psychiatry 1989; 52: 1248–52
   PubMedGoogle Scholar
• Martinot J-L, Peron-Magnan P, Huret J-D, et al. Striatal D2 dopaminergic receptors assessed with positron emission tomography and 76-Br-bromospiperone in untreated patients. Am J Psychiatry 1990; 147: 346–50
   Google Scholar
• Tune L E, Wong D F, Pearlson G, et al. Dopamine D2 receptor density estimates in schizophrenia: a positron emission tomography study with 11C-N-methylspiperone. Psychiatry Res 1993; 49: 219–37
   PubMed Web of Science ®Google Scholar
• Nordstrom A L, Farde L, Eriksson L, Halldin C. No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]N- methylspiperone. Psychiatry Res 1995; 61: 67–83, [see comments]
   PubMed Web of Science ®Google Scholar
• Okubo Y, Suhara T, Suzuki K, et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 1997; 385: 634–6
   PubMed Web of Science ®Google Scholar
• Farde L, Wiesel F, Stone-Elander S, et al. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch Gen Psychiatry 1990; 47: 213–9
   PubMed Web of Science ®Google Scholar
• Hietala J, Syvälahti E, Vuorio K, et al. Striatal D2 receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry 1994; 51: 116–23
   PubMed Web of Science ®Google Scholar
• Pilowsky L S, Costa D C, Ell P J, Verhoeff N PLG, Murray R M, Kerwin R W. D2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An I-123-IBZM single photon emission computerized tomography study. Br J Psychiatry 1994; 164: 16–26
   PubMedGoogle Scholar
• Laruelle M, Abi-Dargham A, van Dyck C H, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug free schizophrenic subjects. Proc Natl Acad Sci U S A 1996; 93: 9235–40
   PubMed Web of Science ®Google Scholar
• Knable M B, Egan M F, Heinz A, et al. Altered dopaminergic function and negative symptoms in drug-free patients with schizophrenia. [123I]-iodobenzamide SPECT study. Br J Psychiatry 1997; 171: 574–7
   PubMedGoogle Scholar
• Breier A, Su T P, Saunders R, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 1997; 94: 2569–74
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A, Gil R, Krystal J, et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 1998; 155: 761–7
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A, Rodenhiser J, Printz D, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 2000; 97: 8104–9
   PubMed Web of Science ®Google Scholar
• Martinot J L, Paillère-Martinot M L, Loc'h C, et al. The estimated density of D2 striatal receptors in schizophrenia. A study with positron emission tomography and 76Br-bromolisuride. Br J Psychiatry 1991; 158: 346–50
   PubMedGoogle Scholar
• Martinot J L, Paillère-Martinot M L, Loc'h C, et al. Central D2 receptors and negative symptoms of schizophrenia. Br J Pharmacol 1994; 164: 27–34
   Google Scholar
• Seeman P, Guan H-C, Niznik H B. Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: Implications for positron emission tomography of the human brain. Synapse 1989; 3: 96–7
   PubMed Web of Science ®Google Scholar
• Seeman P. Brain dopamine receptors in schizophrenia: PET problems. Arch Gen Psychiatry 1988; 45: 598–60
   PubMedGoogle Scholar
• Hirvonen J, van Erp T G, Huttunen J, et al. Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch Gen Psychiatry 2005; 62: 371–8
   PubMed Web of Science ®Google Scholar
• Karlsson P, Farde L, Halldin C, Sedvall G. D1-dopamine receptors in schizophrenia examined by PET. Schizophr Res 1997; 24: 179
   Google Scholar
• Abi-Dargham A, Mawlawi O, Lombardo I, et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 2002; 22: 3708–19
   PubMed Web of Science ®Google Scholar
• Karlsson P, Farde L, Halldin C, Sedvall G. PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry 2002; 159: 761–7
   PubMed Web of Science ®Google Scholar
• Hirvonen J, van Erp T G, Huttunen J, et al. Brain dopamine d1 receptors in twins discordant for schizophrenia. Am J Psychiatry 2006; 163: 1747–53
   PubMed Web of Science ®Google Scholar
• Joyce J N, Lexow N, Bird E, Winokur A. Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia. Synapse 1988; 2: 546–57
   PubMedGoogle Scholar
• Pimoule C, Schoemaker H, Reynolds G P, Langer S Z. [3H]SCH 23390 labelled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. Eur J Pharmacol 1985; 114: 235–7
   PubMedGoogle Scholar
• Seeman P, Bzowej N H, Guan H C, et al. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology 1987; 1: 5–15
   PubMedGoogle Scholar
• Hess E J, Bracha H S, Kleinman J E, Creese I. Dopamine receptor subtype imbalance in schizophrenia. Life Sci 1987; 40: 1487–97
   PubMedGoogle Scholar
• Reith J, Benkelfat C, Sherwin A, et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci U S A 1994; 91: 11651–4
   PubMed Web of Science ®Google Scholar
• Hietala J, Syvalahti E, Vuorio K, et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 1995; 346: 1130–1
   PubMed Web of Science ®Google Scholar
• Dao-Castellana M H, Paillere-Martinot M L, Hantraye P, et al. Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr Res 1997; 23: 167–74
   PubMed Web of Science ®Google Scholar
• Hietala J, Syvalahti E, Vilkman H, et al. Depressive symptoms and presynaptic dopamine function in neuroleptic– naive schizophrenia. Schizophr Res 1999; 35: 41–50
   PubMed Web of Science ®Google Scholar
• McGowan S, Lawrence A D, Sales T, Quested D, Grasby P. Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. Arch Gen Psychiatry 2004; 61: 134–42
   PubMed Web of Science ®Google Scholar
• Elkashef A M, Doudet D, Bryant T, Cohen R M, Li S H, Wyatt R J. 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography. Psychiatry Res 2000; 100: 1–11
   PubMed Web of Science ®Google Scholar
• Lindstrom L H, Gefvert O, Hagberg G, et al. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol Psychiatry 1999; 46: 681–8
   PubMed Web of Science ®Google Scholar
• Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 2000; 20: 423–51
   PubMed Web of Science ®Google Scholar
• Villemagne V L, Wong D F, Yokoi F, et al. GBR12909 attenuates amphetamine-induced striatal dopamine release as measured by [(11)C]raclopride continuous infusion PET scans. Synapse 1999; 33: 268–73
   PubMed Web of Science ®Google Scholar
• Laruelle M, Iyer R N, Al-Tikriti M S, et al. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 1997; 25: 1–14
   PubMedGoogle Scholar
• Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 1999; 46: 56–72
   PubMed Web of Science ®Google Scholar
• Hwang D, Kegeles L S, Laruelle M. (−)-N-[(11)C]propyl-norapomorphine: a positron-labeled dopamine agonist for PET imaging of D(2) receptors. Nucl Med Biol 2000; 27: 533–9
   PubMedGoogle Scholar
• Narendran R, Hwang D R, Slifstein M, et al. Measurement of the proportion of D2 receptors configured in state of high affinity for agonists in vivo: a positron emission tomography study using [11C]N-propyl-norapomorphine and [11C]raclopride in baboons. J Pharmacol Exp Ther 2005; 315: 80–90
   PubMedGoogle Scholar
• Laruelle M D, Souza C D, Baldwin R M, et al. Imaging D-2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 1997; 17: 162–74
   PubMed Web of Science ®Google Scholar
• Fujita M, Verhoeff N P, Varrone A, et al. Imaging extrastriatal dopamine D(2) receptor occupancy by endogenous dopamine in healthy humans. Eur J Pharmacol 2000; 387: 179–88
   PubMedGoogle Scholar
• Laruelle M, Abi-Dargham A, van Dyck C, et al. Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT. Biol Psychiatry 2000; 47: 371–9
   PubMed Web of Science ®Google Scholar
• Laakso A, Vilkman H, Alakare B, et al. Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. Am J Psychiatry 2000; 157: 269–71
   PubMed Web of Science ®Google Scholar
• Laakso A, Bergman J, Haaparanta M, et al. Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophr Res 2001; 52: 115–20
   PubMed Web of Science ®Google Scholar
• Lavalaye J, Linszen D H, Booij J, et al. Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT. Schizophr Res 2001; 47: 59–67
   PubMed Web of Science ®Google Scholar
• Hsiao M C, Lin K J, Liu C Y, Tzen K Y, Yen T C. Dopamine transporter change in drug-naive schizophrenia: an imaging study with 99mTc-TRODAT-1. Schizophr Res 2003; 65: 39–46
   PubMed Web of Science ®Google Scholar
• Yoder K K, Hutchins G D, Morris E D, Brashear A, Wang C, Shekhar A. Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia. Schizophr Res 2004; 71: 371–5
   PubMedGoogle Scholar
• Yang Y K, Yu L, Yeh T L, Chiu N T, Chen P S, Lee I H. Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT study. Am J Psychiatry 2004; 161: 1496–8
   PubMed Web of Science ®Google Scholar
• Mateos J J, Lomena F, Parellada E, et al. Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism. Psychopharmacology (Berl) 2005; 181: 401–6
   PubMedGoogle Scholar
• Schmitt G J, Meisenzahl E M, Frodl T, et al. The striatal dopamine transporter in first-episode, drug-naive schizophrenic patients: evaluation by the new SPECT-ligand[99mTc]TRODAT-1. J Psychopharmacol 2005; 19: 488–93
   PubMed Web of Science ®Google Scholar
• Sjoholm H, Bratlid T, Sundsfjord J. 123I-beta-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia. Psychopharmacology (Berl) 2004; 173: 27–31
   PubMedGoogle Scholar
• Schmitt G J, Frodl T, Dresel S, et al. Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 2006; 256: 115–21
   PubMed Web of Science ®Google Scholar
• Robertson G, Fibiger H. Neuroleptics increase C-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 1992; 46: 315–28
   PubMed Web of Science ®Google Scholar
• Robertson G S, Matsumura H, Fibiger H C. Induction patterns of fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 1994; 271: 1058–66
   PubMed Web of Science ®Google Scholar
• Deutch A, Moghadam B, Innis R, et al. Mechanisms of action of atypical antipsychotic drugs. Implication for novel therapeutic strategies for schizophrenia. Schizophr Res 1991; 4: 121–56
   PubMedGoogle Scholar
• Mawlawi O, Martinez D, Slifstein M, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D2 receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 2001; 21: 1034–57
   PubMed Web of Science ®Google Scholar
• Drevets W C, Gautier C, Price J C, et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 2001; 49: 81–96
   PubMed Web of Science ®Google Scholar
• Martinez D, Slifstein M, Broft A, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 2003; 23: 285–300
   PubMed Web of Science ®Google Scholar
• Halldin C, Farde L, Hogberg T, et al. Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. J Nucl Med 1995; 36: 1275–81
   PubMedGoogle Scholar
• Mukherjee J, Yang Z Y, Das M K, Brown T. Fluorinated benzamide neuroleptics—III. Development of (S)-N-[(1-allyl- 2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. Nucl Med Biol 1995; 22: 283–96
   PubMed Web of Science ®Google Scholar
• De Keyser J, Ebinger G, Vauquelin G. Evidence for a widespread dopaminergic innervation of the human cerebral neocortex. Neurosci Lett 1989; 104: 281–5
   PubMed Web of Science ®Google Scholar
• Hall H, Sedvall G, Magnusson O, Kopp J, Halldin C, Farde L. Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology 1994; 11: 245–56
   PubMedGoogle Scholar
• Okubo Y, Suhara T, Suzuki K, et al. Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography. Life Sci 2000; 66: 2455–64
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A, Gil R, Mawlawi O, et al. Selective alteration in D1 receptors in schizophrenia: a PET in vivo study. J Nuc Med 2001; 42: 17P
   PubMedGoogle Scholar
• Abi-Dargham A, Moore H. Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 2003; 9: 404–16
   PubMed Web of Science ®Google Scholar
• Ekelund J, Narendran R, Guillian O, et al. Pharmacological selectivity of the in vivo binding of [11C]NNC112 and [11C]SCH233390 in the cortex: a PET study in baboons. NeuroImage 2006; 31: T111
   Google Scholar
• Slifstein M, Kegeles L S, Gonzales R, et al. [(11)C]NNC 112 selectivity for dopamine D(1) and serotonin 5-HT(2A) receptors: a PET study in healthy human subjects. J Cereb Blood Flow Metab 2007, Epub Feb 21
   Google Scholar
• Kessler R M, Whetsell W O, Ansari M S, et al. Identification of extrastriatal dopamine D2 receptors in postmortem human brain with [125I]epidipride. Brain Res 1993; 609: 237–43
   PubMedGoogle Scholar
• Lidow M S, Goldman-Rakic P S, Rakic P, Innis R B. Dopamine D2 receptors in the cerebral cortex: distribution and pharmacological characterization with [3H]raclopride. Proc Natl Acad Sci U S A 1989; 86: 6412–6
   PubMed Web of Science ®Google Scholar
• Murray A, Ryoo H L, Gurevich E, Joyce J N. Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesofrontal regions of human forebrain. Proc Natl Acad Sci U S A 1994; 91: 11271–5
   PubMed Web of Science ®Google Scholar
• Joyce J N, Janowsky A, Neve K. Characterization and distribution of [125I]epidepride binding to dopamine D2 receptors in basal ganglia and cortex in human brain. J Pharmacol Exp Ther 1991; 257: 1253–63
   PubMedGoogle Scholar
• Slifstein M, Hwang D R, Huang Y, et al. In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates. Psychopharmacology (Berl) 2004; 175: 274–86
   PubMedGoogle Scholar
• Talvik M, Nordstrom A L, Olsson H, Halldin C, Farde L. Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457. Int J Neuropsychopharmacol 2003; 6: 361–70
   PubMed Web of Science ®Google Scholar
• Yasuno F, Suhara T, Okubo Y, et al. Low dopamine d(2) receptor binding in subregions of the thalamus in schizophrenia. Am J Psychiatry 2004; 161: 1016–22
   PubMed Web of Science ®Google Scholar
• Buchsbaum M S, Christian B T, Lehrer D S, et al. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res 2006; 85: 232–44
   PubMed Web of Science ®Google Scholar
• Suhara T, Okubo Y, Yasuno F, et al. Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiatry 2002; 59: 25–30
   PubMed Web of Science ®Google Scholar
• Tuppurainen H, Kuikka J T, Laakso M P, Viinamaki H, Husso M, Tiihonen J. Midbrain dopamine D(2/3) receptor binding in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2006; 256: 382–7
   PubMedGoogle Scholar
• Tuppurainen H, Kuikka J, Viinamaki H, Husso-Saastamoinen M, Bergstrom K, Tiihonen J. Extrastriatal dopamine D 2/3 receptor density and distribution in drug-naive schizophrenic patients. Mol Psychiatry 2003; 8: 453–5
   PubMed Web of Science ®Google Scholar
• Glenthoj B Y, Mackeprang T, Svarer C, et al. Frontal dopamine D(2/3) receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender. Biol Psychiatry 2006; 60: 621–9
   PubMed Web of Science ®Google Scholar
• Mukherjee J, Yang Z Y, Lew R, et al. Evaluation of d-amphetamine effects on the binding of dopamine D-2 receptor radioligand, F-18-fallypride in nonhuman primates using positron emission tomography. Synapse 1997; 27: 1–13
   PubMed Web of Science ®Google Scholar
• Slifstein M, Narendran R, Hwang D R, et al. Effect of amphetamine on [(18)F]fallypride in vivo binding to D(2) receptors in striatal and extrastriatal regions of the primate brain: single bolus and bolus plus constant infusion studies. Synapse 2004; 54: 46–63
   PubMedGoogle Scholar
• Mukherjee J, Christian B T, Narayanan T K, Shi B, Collins D. Measurement of d-amphetamine-induced effects on the binding of dopamine D-2/D-3 receptor radioligand, 18F-fallypride in extrastriatal brain regions in non-human primates using PET. Brain Res 2005; 1032: 77–84
   PubMed Web of Science ®Google Scholar
• Riccardi P, Li R, Ansari M S, et al. Amphetamine-induced displacement of [18F] fallypride in striatum and extrastriatal regions in humans. Neuropsychopharmacology 2006; 31: 1016–26
   PubMedGoogle Scholar
• Christian B T, Lehrer D S, Shi B, et al. Measuring dopamine neuromodulation in the thalamus: using [F-18]fallypride PET to study dopamine release during a spatial attention task. Neuroimage 2006; 31: 139–52
   PubMed Web of Science ®Google Scholar
• Gaddum J H. Drug antagonistic to 5-hydroxytryptamine. Ciba foundation symposium on hypertension, G W Wolstenholme. Little Brown, Boston 1954; 75–7
   Google Scholar
• Wooley D W, Shaw E. A biological and pharmacological suggestion about certain mental disorder. Proc Natl Acad Sci U S A 1954; 40: 228–31
   PubMed Web of Science ®Google Scholar
• Aghajanian G K, Marek G J. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Brain Res Rev 2000; 31: 302–12
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A, Laruelle M, Aghajanian G K, Charney D, Krystal J. The role of serotonin in the pathophysiology and treatment of schizophrenia. J Neuropsych Clin Neurosci 1997; 9: 1–17
   PubMed Web of Science ®Google Scholar
• Neumeyer J L, Wang S, Milius R A, et al. [123I]2β-carbomethoxy-3β-(4-iodophenyl)tropane (β-CIT): high affinity SPECT radiotracer of monoamine reuptake sites in brain. J Med Chem 1991; 34: 3144–6
   PubMed Web of Science ®Google Scholar
• Laruelle M, Baldwin R M, Malison R T, et al. SPECT imaging of dopamine and serotonin transporters with [123I]β -CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993; 13: 295–309
   PubMed Web of Science ®Google Scholar
• Frankle W G, Narendran R, Huang Y, et al. Serotonin transporter availability in patients with schizophrenia: a positron emission tomography imaging study with [11C]DASB. Biol Psychiatry 2005; 57: 1510–6
   PubMedGoogle Scholar
• Joyce J N, Shane A, Lexow N, Winokur A, Casanova M F, Kleinman J E. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 1993; 8: 315–36
   PubMed Web of Science ®Google Scholar
• Laruelle M, Abi-Dargham A, Casanova M F, Toti R, Weinberger D R, Kleinman J E. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia: a postmortem study. Arch Gen Psychiatry 1993; 50: 810–8
   PubMed Web of Science ®Google Scholar
• Gurevich E V, Joyce J N. Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol Psychiatry 1997; 42: 529–45
   PubMed Web of Science ®Google Scholar
• Dean B, Opeskin K, Pavey G, et al. [3H]paroxetine binding is altered in the hippocampus but not the frontal cortex or caudate nucleus from subjects with schizophrenia. J Neurochem 1995; 64: 1197–202
   PubMed Web of Science ®Google Scholar
• Naylor L, Dean B, Opeskin K, et al. Changes in the serotonin transporter in the hippocampus of subjects with schizophrenia identified using [3H]paroxetine. J Neural Transm Gen Sect 1996; 103: 749–57
   PubMed Web of Science ®Google Scholar
• Frankle W G, Huang Y, Hwang D R, et al. Comparative evaluation of serotonin transporter radioligands 11C-DASB and 11C-McN 5652 in healthy humans. J Nucl Med 2004; 45: 682–94
   PubMedGoogle Scholar
• Huang Y, Hwang D R, Narendran R, et al. Comparative evaluation in nonhuman primates of five PET radiotracers for imaging the serotonin transporters: [11C]McN 5652, [11C]ADAM, [11C]DASB, [11C]DAPA, and [11C]AFM. J Cereb Blood Flow Metab 2002; 22: 1377–98
   PubMed Web of Science ®Google Scholar
• Huang Y, Bae S-A, Zhu Z, Guo N, Hwang D R, Laruelle M. Fluorinated analogues of ADAM as new PET radioligands for the serotonin transporter: synthesis and pharmacological evaluation. J Labelled Compd Radiopharm 2001; 44: S18–20
   Google Scholar
• Bennett J P, Enna S J, Bylund D B, Gillin J C, Wyatt R J, Snyder S H. Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry 1979; 36: 927–34
   PubMed Web of Science ®Google Scholar
• Whitaker P M, Crow T J, Ferrier I N. Tritiated LSD binding in frontal cortex in schizophrenia. Arch Gen Psychiatry 1981; 38: 278–80
   PubMed Web of Science ®Google Scholar
• Reynolds G P, Rossor M N, Ivesen L L. Preliminary studies of human cortical 5-HT2 receptors and their involvement in schizophrenia and neuroleptic drug action. J Neural Transm 1983; 273–7, suppl 18
   Google Scholar
• Mita T, Hanada S, Nishino N, et al. Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol Psychiatry 1986; 21: 1407–14
   PubMed Web of Science ®Google Scholar
• Arora R C, Meltzer H Y. Serotonin2 (5-HT2) receptor binding in frontal cortex of schizophrenic patients. J Neural Transm 1991; 85: 19–29
   PubMed Web of Science ®Google Scholar
• Dean B, Hayes W. Decreased frontal cortical serotonin2A receptors in schizophrenia. Schizophr Res 1996; 21: 133–9
   PubMed Web of Science ®Google Scholar
• Burnet P W, Eastwood S L, Harrison P J. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 1996; 15: 442–55
   PubMed Web of Science ®Google Scholar
• Lewis R, Kapur S, Jones C, et al. Serotonin 5-HT2 receptors in schizophrenia: a PET study using [18F]setoperone in neuroleptic-naive patients and normal subjects. Am J Psychiatry 1999; 156: 72–8
   PubMed Web of Science ®Google Scholar
• Trichard C, Paillere-Martinot M L, Attar-Levy D, Blin J, Feline A, Martinot J L. No serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET. Schizophr Res 1998; 31: 13–7
   PubMed Web of Science ®Google Scholar
• Verhoeff N P, Meyer J H, Kecojevic A, et al. A voxel-by-voxel analysis of [18F]setoperone PET data shows no substantial serotonin 5-HT(2A) receptor changes in schizophrenia. Psychiatry Res 2000; 99: 123–35
   PubMed Web of Science ®Google Scholar
• Ngan E T, Yatham L N, Ruth T J, Liddle P F. Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia: a PET study using [(18)F]setoperone. Am J Psychiatry 2000; 157: 1016–8
   PubMed Web of Science ®Google Scholar
• Burnet P WJ, Eastwood S L, Harrison P J. [H-3]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [H-3]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem Int 1997; 30: 565–74
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Nishino N, Nakai H, Tanaka C. Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci 1991; 48: 355–63
   PubMed Web of Science ®Google Scholar
• Simpson M D, Lubman D I, Slater P, Deakin J F. Autoradiography with [3H]8-OH-DPAT reveals increases in 5-HT(1A) receptors in ventral prefrontal cortex in schizophrenia. Biol Psychiatry 1996; 39: 919–28
   PubMed Web of Science ®Google Scholar
• Sumiyoshi T, Stockmeier C A, Overholser J C, Dilley G E, Meltzer H Y. Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res 1996; 708: 209–14
   PubMed Web of Science ®Google Scholar
• Tauscher J, Kapur S, Verhoeff N P, et al. Brain serotonin 5-HT1A receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Arch Gen Psychiatry 2002; 59: 514–20
   PubMed Web of Science ®Google Scholar
• Yasuno F, Suhara T, Ichimiya T, Takano A, Ando T, Okubo Y. Decreased 5-HT1A receptor binding in amygdala of schizophrenia. Biol Psychiatry 2004; 55: 439–44
   PubMedGoogle Scholar
• Frankle W G, Lombardo I, Kegeles L S, et al. Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: a positron emission tomography imaging study with [(11)C]WAY 100635. Psychopharmacology (Berl) 2006; 189: 155–64
   PubMed Web of Science ®Google Scholar
• Cruz D A, Eggan S M, Azmitia E C, Lewis D A. Serotonin1A receptors at the axon initial segment of prefrontal pyramidal neurons in schizophrenia. Am J Psychiatry 2004; 161: 739–42
   PubMedGoogle Scholar
• Lewis D A. GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia. Brain Res Rev 2000; 31: 270–6
   PubMedGoogle Scholar
• Benes F M. Emerging principles of altered neural circuitry in schizophrenia. Brain Res Rev 2000; 31: 251–69
   PubMed Web of Science ®Google Scholar
• Busatto G F, Pilowsky L S, Costa D C, et al. Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. Am J Psychiatry 1997; 154: 56–63
   PubMed Web of Science ®Google Scholar
• Verhoeff N P, Soares J C, D'Souza C D, et al. [123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia. Psychiatry Res 1999; 91: 163–73
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A, Laruelle M, Krystal J, et al. No evidence of altered in vivo benzodiazepine receptor binding in schizophrenia. Neuropsychopharmacology 1999; 20: 650–61
   PubMed Web of Science ®Google Scholar
• Benes F M, Wickramasinghe R, Vincent S L, Khan Y, Todtenkopf M. Uncoupling of GABA(A) and benzodiazepine receptor binding activity in the hippocampal formation of schizophrenic brain. Brain Res 1997; 755: 121–9
   PubMedGoogle Scholar
• Lewis D A, Hashimoto T, Volk D W. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 2005; 6: 312–24
   PubMed Web of Science ®Google Scholar
• Raedler T J, Knable M B, Jones D W, et al. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry 2003; 160: 118–27
   PubMed Web of Science ®Google Scholar
• Crook J M, Tomaskovic-Crook E, Copolov D L, Dean B. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry 2000; 48: 381–8
   PubMed Web of Science ®Google Scholar
• Crook J M, Tomaskovic-Crook E, Copolov D L, Dean B. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry 2001; 158: 918–25
   PubMed Web of Science ®Google Scholar
• Dean B, Crook J M, Opeskin K, Hill C, Keks N, Copolov D L. The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol Psychiatry 1996; 1: 54–8
   PubMed Web of Science ®Google Scholar
• Watanabe S, Nishikawa T, Takashima M, Toru M. Increased muscarinic cholinergic receptors in prefrontal cortices of medicated schizophrenics. Life Sci 1983; 33: 2187–96
   PubMed Web of Science ®Google Scholar
• Owen F, Cross A J, Crow T J, Lofthouse R, Poulter M. Neurotransmitter receptors in brain in schizophrenia. Acta Psychiatr Scand Suppl 1981; 291: 20–8
   PubMedGoogle Scholar
• Yanai K, Tashiro M. The physiological and pathophysiological roles of neuronal histamine: an insight from human positron emission tomography studies. Pharmacol Ther 2007; 113: 1–15
   PubMed Web of Science ®Google Scholar
• Iwabuchi K, Ito C, Tashiro M, et al. Histamine H1 receptors in schizophrenic patients measured by positron emission tomography. Eur Neuropsychopharmacol 2005; 15: 185–91
   PubMedGoogle Scholar
• Vander Borght T, Kilbourn M, Desmond T, Kuhl D, Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 1995; 294: 577–83
   PubMed Web of Science ®Google Scholar
• Taylor S F, Koeppe R A, Tandon R, Zubieta J K, Frey K A. In vivo measurement of the vesicular monoamine transporter in schizophrenia. Neuropsychopharmacology 2000; 23: 667–75
   Google Scholar
• Regier D A, Farmer M E, Rae D S, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264: 2511–8
   PubMed Web of Science ®Google Scholar
• Arseneault L, Cannon M, Witton J, Murray R M. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004; 184: 110–7
   PubMed Web of Science ®Google Scholar
• Devane W A, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946–9
   PubMed Web of Science ®Google Scholar
• Matsuda L A, Lolait S J, Brownstein M J, Young A C, Bonner T I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561–4
   PubMed Web of Science ®Google Scholar
• Matsuda L A. Molecular aspects of cannabinoid receptors. Crit Rev Neurobiol 1997; 11: 143–66
   PubMedGoogle Scholar
• Glass M, Dragunow M, Faull R L. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997; 77: 299–318
   PubMed Web of Science ®Google Scholar
• Biegon A, Kerman I A. Autoradiographic study of pre- and postnatal distribution of cannabinoid receptors in human brain. Neuroimage 2001; 14: 1463–8
   PubMed Web of Science ®Google Scholar
• Herkenham M, Lynn A B, Little M D, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 1990; 87: 1932–6
   PubMed Web of Science ®Google Scholar
• Pazos M R, Nunez E, Benito C, Tolon R M, Romero J. Functional neuroanatomy of the endocannabinoid system. Pharmacol Biochem Behav 2005; 81: 239–47
   PubMedGoogle Scholar
• Giuffrida A, Leweke F M, Gerth C W, et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 2004; 29: 2108–14
   PubMed Web of Science ®Google Scholar
• Dean B, Sundram S, Bradbury R, Scarr E, Copolov D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001; 103: 9–15
   PubMed Web of Science ®Google Scholar
• Zavitsanou K, Garrick T, Huang X F. Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 355–60
   PubMed Web of Science ®Google Scholar
• Horti A, Fan H, Ravert H T, et al. PET Imaging of cerebral cannabinoid CB1 receptors with [11C]JHU75528. J Nuc Med 2006; 136, 2006
   Google Scholar
• Kapur S, Zipursky R B, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999; 156: 286–93
   PubMed Web of Science ®Google Scholar
• Nyberg S, Nilsson U, Okubo Y, Halldin C, Farde L. Implications of brain imaging for the management of schizophrenia. Int Clin Psychopharmacol 1998; 13: S15–20, suppl 3
   Google Scholar
• Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261: 717–9
   PubMed Web of Science ®Google Scholar
• Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975; 188: 1217–9
   PubMed Web of Science ®Google Scholar
• Seeman P, Chau-Wong M, Tedesco J, Wong K. Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci U S A 1975; 72: 4376–80
   PubMed Web of Science ®Google Scholar
• Farde L, Nordström A L, Wiesel F A, Pauli S, Halldin C, Sedvall G. Positron emission tomography analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 1992; 49: 538–44
   PubMed Web of Science ®Google Scholar
• Wolkin A, Barouche F, Wolf A P, et al. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 1989; 146: 905–8
   PubMed Web of Science ®Google Scholar
• Pilowsky L S, Costa D C, Ell P J, Murray R M, Verhoeff N PLG, Kerwin R W. Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 1992; 340: 199–202
   PubMed Web of Science ®Google Scholar
• Nordstrom A L, Farde L, Wiesel F A, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993; 33: 227–35
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157: 514–20
   PubMed Web of Science ®Google Scholar
• Kane J, Honigfeld G, Singer J, Meltzer H Y. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988; 45: 789–96
   PubMed Web of Science ®Google Scholar
• Kane J M, Marder S R, Schooler N R, et al. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry 2001; 58: 965–72
   PubMedGoogle Scholar
• Kane J M. Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol 2001; 11: S397–403, suppl 4
   PubMed Web of Science ®Google Scholar
• Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 2001; 158: 360–9
   PubMed Web of Science ®Google Scholar
• Lidsky T I. Reevaluation of the mesolimbic hypothesis of antipsychotic drug action. Schizophr Bull 1995; 21: 67–74
   PubMedGoogle Scholar
• Meltzer H Y, Matsubara S, Lee J C. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989; 25: 390–2
   PubMed Web of Science ®Google Scholar
• Nordstrom A L, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995; 152: 1444–9
   PubMed Web of Science ®Google Scholar
• Kapur S, Roy P, Daskalakis J, Remington G, Zipursky R. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am J Psychiatry 2001; 158: 311–4
   PubMed Web of Science ®Google Scholar
• Chivers J K, Gommeren W, Leysen J E, Jenner P, Marsden C D. Comparison of the in-vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors. J Pharm Pharmacol 1988; 40: 415–21
   PubMedGoogle Scholar
• Leucht S, Pitschel-Walz G, Engel R R, Kissling W. Amisulpride, an unusual “atypical” antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002; 159: 180–90
   PubMed Web of Science ®Google Scholar
• Xiberas X, Martinot J L, Mallet L, et al. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. J Clin Psychopharmacol 2001; 21: 207–14
   PubMed Web of Science ®Google Scholar
• Bressan R A, Erlandsson K, Jones H M, et al. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? An in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. Am J Psychiatry 2003; 160: 1413–20
   PubMedGoogle Scholar
• Vernaleken I, Siessmeier T, Buchholz H G, et al. High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. Int J Neuropsychopharmacol 2004; 7: 421–30
   PubMedGoogle Scholar
• Gefvert O, Bergstrom M, Langstrom B, Lundberg T, Lindstrom L, Yates R. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (Berl) 1998; 135: 119–26
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky R, Jones C, Shammi C S, Remington G, Seeman P. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000; 57: 553–9
   PubMed Web of Science ®Google Scholar
• Tauscher-Wisniewski S, Kapur S, Tauscher J, et al. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. J Clin Psychiatry 2002; 63: 992–7
   PubMed Web of Science ®Google Scholar
• Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci 2000; 25: 161–6
   PubMed Web of Science ®Google Scholar
• Meisenzahl E M, Dresel S, Frodl T, et al. D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study. J Psychopharmacology 2000; 14: 364–70
   PubMed Web of Science ®Google Scholar
• Raedler T J, Knable M B, Lafargue T, et al. In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine. Psychiatry Res 1999; 90: 81–90
   PubMedGoogle Scholar
• Kapur S, Zipursky R B, Remington G, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998; 155: 921–8
   PubMed Web of Science ®Google Scholar
• Lavalaye J, Booij J, Linszen D H, Reneman L, van Royen E A. Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A[123I]-IDEX SPECT study. Psychopharmacology (Berl) 2001; 156: 53–7
   PubMedGoogle Scholar
• Raedler T J, Knable M B, Jones D W, et al. In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia. Neuropsychopharmacology 2000; 23: 56–68
   PubMed Web of Science ®Google Scholar
• Anden N E. Dopamine turnover in the corpus striatum and the lumbic system after treatment with neuroleptic and anti-acetylcholine drugs. J Pharm Pharmacol 1972; 24: 905–6
   PubMed Web of Science ®Google Scholar
• Anden N, Stock G. Effect of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system. J Pharm Pharmacol 1973; 25: 346–8
   PubMed Web of Science ®Google Scholar
• Matthysse S. Dopamine and the pharmacology of schizophrenia: the state of the evidence. J Psychiatr Res 1974; 11: 107–13
   PubMedGoogle Scholar
• Matthysse S. Antipsychotic drug actions: a clue to the neuropathology of schizophrenia?. Fed Proc 1973; 32: 200–5
   PubMedGoogle Scholar
• Snyder S H. Cathecolamines in the brain as mediator of amphetamine psychosis. Arch Gen Psychiatry 1972; 27: 169–79
   PubMed Web of Science ®Google Scholar
• Stevens J. An anatomy of schizophrenia?. Arch Gen Psychiatry 1973; 29: 177–89
   PubMed Web of Science ®Google Scholar
• Deutch A Y, Lee M C, Iadarola M J. Regionally specific effects of atypical antipsychotic drugs on striatal fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Mol Cell Neurosci 1992; 3: 332–41
   PubMed Web of Science ®Google Scholar
• Robertson G S, Fibiger H C. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 1992; 46: 315–28
   PubMed Web of Science ®Google Scholar
• Grace A A, Bunney B S, Moore H, Todd C L. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci 1997; 20: 31–7
   PubMed Web of Science ®Google Scholar
• Chiodo L, Bunney B. Typical and atypical neiroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 1983; 3: 1607–19
   PubMed Web of Science ®Google Scholar
• White F J, Wang R Y. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 1983; 1054–7
   PubMedGoogle Scholar
• Pilowsky L S, Mulligan R S, Acton P D, Ell P J, Costa D C, Kerwin R W. Limbic selectivity of clozapine. Lancet 1997; 350: 490–1
   PubMed Web of Science ®Google Scholar
• Farde L, Suhara T, Nyberg S, et al. A PET study of [C-11]FLB 457 binding to extrastriatal D-2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology 1997; 133: 396–404
   PubMed Web of Science ®Google Scholar
• Bigliani V, Mulligan R S, Acton P D, et al. In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs. [123I]epidepride single photon emission tomography (SPET) study. Br J Psychiatry 1999; 175: 231–8
   PubMed Web of Science ®Google Scholar
• Bigliani V, Mulligan R S, Acton P D, et al. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study. Psychopharmacology (Berl) 2000; 150: 132–40
   PubMedGoogle Scholar
• Stephenson C, Bigliani V, Jones H, et al. Striatal and extra-striatal D2/D3 dopamine receptor occupancy by quetiapine in vivo. Br J Psychiatry 2000; 177: 408–15
   PubMedGoogle Scholar
• Talvik M, Nordstrom A L, Nyberg S, Olsson H, Halldin C, Farde L. No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457. Am J Psychiatry 2001; 158: 926–30
   PubMed Web of Science ®Google Scholar
• Xiberas X, Martinot J L, Mallet L, et al. Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry 2001; 179: 503–8
   PubMed Web of Science ®Google Scholar
• Yasuno F, Suhara T, Okubo Y, et al. Dose relationship of limbic-cortical D2-dopamine receptor occupancy with risperidone. Psychopharmacology (Berl) 2001; 154: 112–4
   PubMedGoogle Scholar
• Bressan R A, Erlandsson K, Jones H M, Mulligan R S, Ell P J, Pilowsky L S. Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study. J Clin Psychopharmacol 2003; 23: 5–14
   PubMedGoogle Scholar
• Kessler R M, Ansari M S, Riccardi P, et al. Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol. Neuropsychopharmacology 2005; 30: 2283–9
   PubMedGoogle Scholar
• Kessler R M, Ansari M S, Riccardi P, et al. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 2006; 31: 1991–2001
   PubMed Web of Science ®Google Scholar
• Grunder G, Landvogt C, Vernaleken I, et al. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology 2006; 31: 1027–35
   PubMed Web of Science ®Google Scholar
• Agid O, Mamo D, Ginovart N, et al. Striatal vs extrastriatal dopamine D(2) receptors in antipsychotic response—a double-blind PET study in schizophrenia. Neuropsychopharmacology 2007; 32: 1209–15
   PubMed Web of Science ®Google Scholar
• Olsson H, Farde L. Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy—a simulation study based on experimental data. Neuroimage 2001; 14: 936–45
   PubMedGoogle Scholar
• Khan Z U, Mrzljak L, Gutierrez A, de la Calle A, Goldman-Rakic P S. Prominence of the dopamine D2 short isoform in dopaminergic pathways. Proc Natl Acad Sci U S A 1998; 95: 7731–6
   PubMed Web of Science ®Google Scholar
• Karle J, Clemmesen L, Hansen L, et al. NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia. Psychopharmacology (Berl) 1995; 121: 328–9
   PubMed Web of Science ®Google Scholar
• de Beaurepaire R, Labelle A, Naber D, Jones B D, Barnes T R. An open trial of the D1 antagonist SCH 39166 in six cases of acute psychotic states. Psychopharmacology (Berl) 1995; 121: 323–7
   PubMed Web of Science ®Google Scholar
• Den Boer J A, van Megen H J, Fleischhacker W W, et al. Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia. Psychopharmacology (Berl) 1995; 121: 317–22
   PubMed Web of Science ®Google Scholar
• Karlsson P, Smith L, Farde L, Harnryd C, Sedvall G, Wiesel F A. Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology (Berl) 1995; 121: 309–16
   PubMed Web of Science ®Google Scholar
• Tauscher J, Hussain T, Agid O, et al. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am J Psychiatry 2004; 161: 1620–5
   PubMed Web of Science ®Google Scholar
• Goldman-Rakic P S, Selemon L D. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull 1997; 23: 437–58
   PubMed Web of Science ®Google Scholar
• Goldman-Rakic P S, Muly E C, 3rd, Williams G V. D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev 2000; 31: 295–301
   PubMed Web of Science ®Google Scholar
• Goldman-Rakic P S. The physiological approach: functional architecture of working memory and disordered cognition in schizophrenia. Biol Psychiatry 1999; 46: 650–61
   PubMed Web of Science ®Google Scholar
• Chou Y H, Halldin C, Farde L. Clozapine binds preferentially to cortical D1-like dopamine receptors in the primate brain: a PET study. Psychopharmacology (Berl) 2006; 185: 29–35
   PubMedGoogle Scholar
• Schotte A, Janssen P F, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996; 124: 57–73
   PubMed Web of Science ®Google Scholar
• Lidow M S, Goldman-Rakic P S, Gallager D W, Geschwind D H, Rakic P. Distribution of major neurotransmitter receptors in the motor and somatosensory cortex of the rhesus monkey. Neuroscience 1989; 32: 609–27
   PubMedGoogle Scholar
• Meltzer H Y, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1159–72
   PubMed Web of Science ®Google Scholar
• Meltzer H Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999; 21: 106S–15S
   PubMed Web of Science ®Google Scholar
• Schmidt A W, Lebel L A, Howard H R, Jr., Zorn S H. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001; 425: 197–201
   PubMed Web of Science ®Google Scholar
• Trichard C, Paillere-Martinot M L, Attar-Levy D, Recassens C, Monnet F, Martinot J L. Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am J Psychiatry 1998; 155: 505–8
   PubMedGoogle Scholar
• Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenia patients. Am J Psychiatry 1999; 156: 869–75
   PubMed Web of Science ®Google Scholar
• Gefvert O, Lundberg T, Wieselgren I, et al. D2 and 5HT2a receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol 2001; 11: 105–10
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky R, Jones C, Shammi C, Remington G, Seeman P. A positron emission tomoghraphy study of quetiapine in schizophrenia. Arch Gen Psychiatry 2000; 57: 553–9
   PubMed Web of Science ®Google Scholar
• Mamo D, Kapur S, Shammi C M, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 2004; 161: 818–25
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky R, Remington G, Jones C, McKay G, Houle S. PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry 1997; 154: 1525–9
   PubMed Web of Science ®Google Scholar
• Singh A N, Barlas C, Singh S, Franks P, Mishra R K. A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes. J Psychiatry Neurosci 1996; 21: 29–35
   PubMed Web of Science ®Google Scholar
• Nyberg S, Farde L, Eriksson L, Halldin C, Eriksson B. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology 1993; 110: 265–72
   PubMed Web of Science ®Google Scholar
• Kapur S, Remington G, Zipursky R B, Wilson A A, Houle S. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 1995; 57: PL103–7
   PubMed Web of Science ®Google Scholar
• Knable M B, Heinz A, Raedler T, Weinberger D R. Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. Psychiat Res Neuroimag 1997; 75: 91–101
   PubMed Web of Science ®Google Scholar
• Kuroki T, Meltzer H Y, Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 1999; 288: 774–81
   PubMed Web of Science ®Google Scholar
• Sumiyoshi T, Matsui M, Nohara S, et al. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 2001; 158: 1722–5
   PubMed Web of Science ®Google Scholar
• Sumiyoshi T, Matsui M, Yamashita I, et al. The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biol Psychiatry 2001; 49: 861–8
   PubMed Web of Science ®Google Scholar
• Goff D C, Midha K K, Brotman A W, McCormick S, Waites M, Amico E T. An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol 1991; 11: 193–7
   PubMed Web of Science ®Google Scholar
• Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar C A. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor. Eur J Pharmacol 2002; 441: 137–40
   PubMed Web of Science ®Google Scholar
• Newman-Tancredi A, Gavaudan S, Conte C, et al. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol 1998; 355: 245–56
   PubMed Web of Science ®Google Scholar
• Frankle W, Lombardo I, Kegeles L, et al. Occupancy of ziprasidone at the 5-HT1a receptor in patients with schizophrenia measured using [11C]WAY-100635. Proceedings of the Annual Meeting of the Society of Nuclear Medicine, Toronto, June, 2005
   Google Scholar
• Bantick R A, Montgomery A J, Bench C J, et al. A positron emission tomography study of the 5-HT1A receptor in schizophrenia and during clozapine treatment. J Psychopharmacol 2004; 18: 346–54
   PubMedGoogle Scholar
• Andree B, Hedman A, Thorberg S O, Nilsson D, Halldin C, Farde L. Positron emission tomographic analysis of dose-dependent NAD-299 binding to 5-hydroxytryptamine-1A receptors in the human brain. Psychopharmacology (Berl) 2003; 167: 37–45
   PubMed Web of Science ®Google Scholar
• Martinez D, Hwang D, Mawlawi O, et al. Differential occupancy of somatodendritic and postsynaptic 5HT(1A) receptors by pindolol. A dose-occupancy study with [11C]WAY 100635 and positron emission tomography in humans. Neuropsychopharmacology 2001; 24: 209–29
   PubMed Web of Science ®Google Scholar
• Bantick R A, Rabiner E A, Hirani E, de Vries M H, Hume S P, Grasby P M. Occupancy of agonist drugs at the 5-HT1A receptor. Neuropsychopharmacology 2004; 29: 847–59
   PubMedGoogle Scholar
• Kumar J S, Majo V J, Hsiung S C, et al. Synthesis and in vivo validation of [O-methyl-11C]2-4-[4-(7-methoxynaphthalen-1-yl)piperazin- 1-yl]butyl-4-methyl-2H-[1,2,4]triazine-3,5-dione: a novel 5-HT1A receptor agonist positron emission tomography ligand. J Med Chem 2006; 49: 125–34
   PubMedGoogle Scholar
• Prabhakaran J, Parsey R V, Majo V J, et al. Synthesis, in vitro and in vivo evaluation of [O-methyl-11C] 2-4-[4-(3-methoxyphenyl)piperazin-1-yl]-butyl-4-methyl-2H-[1,2,4]-triazi ne-3,5-dione: a novel agonist 5-HT1A receptor PET ligand. Bioorg Med Chem Lett 2006; 16: 2101–4
   PubMedGoogle Scholar
• Narendran R, Hwang D R, Slifstein M, et al. In vivo vulnerability to competition by endogenous dopamine: comparison of the D2 receptor agonist radiotracer (−)-N-[11C]propyl-norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]-raclopride. Synapse 2004; 52: 188–208
   PubMedGoogle Scholar
• In vivo neuroreceptor imaging techniques in psychiatric drug development, D Dougherty, N Alpert, S Rauch, A Fischman. American Psychiatric Publishing, Washington, DC 2001
   Google Scholar
• Glazer W M, Kane J M. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 1992; 53: 426–33
   PubMed Web of Science ®Google Scholar
• Johnson D A. Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. J Clin Psychiatry 1984; 45: 13–21
   PubMedGoogle Scholar
• Gefvert O, Eriksson B, Persson P, et al. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol 2005; 8: 27–36
   PubMed Web of Science ®Google Scholar
• Remington G, Mamo D, Labelle A, et al. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry 2006; 163: 396–401
   PubMed Web of Science ®Google Scholar
• Carlsson A, Waters N, Carlsson M L. Neurotransmitter interactions in schizophrenia—therapeutic implications. Biol Psychiatry 1999; 46: 1388–95
   PubMed Web of Science ®Google Scholar
• Carr D B, Sesack S R. Projections from the rat prefrontal cortex to the ventral tegmental area: target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons. J Neurosci 2000; 20: 3864–73
   PubMed Web of Science ®Google Scholar
• Karreman M, Moghaddam B. The prefrontal cortex regulates the basal release of dopamine in the limbic striatum: an effect mediated by ventral tegmental area. J Neurochem 1996; 66: 589–98
   PubMedGoogle Scholar
• Goff D C, Coyle J T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001; 158: 1367–77
   PubMed Web of Science ®Google Scholar
• Goff D C, Tsai G, Levitt J, et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 1999; 56: 21–7
   PubMed Web of Science ®Google Scholar
• van Berckel B N, Kegeles L S, Waterhouse R, et al. Modulation of amphetamine-induced dopamine release by group II metabotropic glutamate receptor agonist LY354740 in non-human primates studied with positron emission tomography. Neuropsychopharmacology 2006; 31: 967–77
   PubMed Web of Science ®Google Scholar
• Schoepp D D. New directions in the treatment of schizophrenia: modulators of mGlu2 and/or mGlu3 receptors. Proceedings of the Annual Meeting of the American College of Neuropsychopharmacology, Hollywood, FL, December, 2006
   Google Scholar
• Moghaddam B, Adams B W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998; 281: 1349–52
   PubMed Web of Science ®Google Scholar
• Tsukada H, Harada N, Ohba H, Nishiyama S, Kakiuchi T. Facilitation of dopaminergic neural transmission does not affect [11C]SCH23390 binding to the striatal D1 dopamine receptors, but the facilitation enhances phosphodiesterase type-IV activity through D1 receptors: PET studies in the conscious monkey brain. Synapse 2001; 42: 258–65
   PubMedGoogle Scholar